Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-04EMA Authorised: SomaKit TOC (edotreotide) — Novartis Europharm Limited
EMA authorised SomaKit TOC (edotreotide) for neuroendocrine tumors and radionuclide imaging.
-
EMA approval · 2026-01-22EMA Authorised: Bavencio (avelumab) — Merck Europe B.V.
The European Medicines Agency authorised a new indication for Bavencio (avelumab) for neuroendocrine tumors.
-
EMA approval · 2025-12-08EMA Authorised: Xermelo (telotristat etiprate) — SERB SAS
EMA authorised Xermelo (telotristat etiprate) for the treatment of carcinoid syndrome–related diarrhea in adults with neuroendocrine tumors,…
-
FDA approval · 2025-12-05FDA Approved: ILLUCCIX — Supplemental Application (Telix Pharmaceuticals (US) Inc.)
FDA approves a supplemental application for ILLUCCIX, a kit for preparing gallium-68 gozetotide injection used in PET imaging. This marks an…
-
EMA approval · 2025-12-04EMA Authorised: Sunitinib Accord (sunitinib) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Sunitinib Accord for the treatment of gastrointestinal stromal tumors, renal cell carcinoma, and ne…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-11-12EMA Authorised: Lutathera (lutetium (177Lu) oxodotreotide) — Advanced Accelerator Applications
European Medicines Agency authorized Lutathera (lutetium (177Lu) oxodotreotide) for neuroendocrine tumors; the product is designated as an o…
-
FDA approval · 2025-09-11FDA Approved: ILLUCCIX — Supplemental Application (Telix Pharmaceuticals (US) Inc.)
FDA approved a supplemental application for ILLUCCIX, a kit for the preparation of gallium-68 gozetotide injection, for use in PET imaging o…
-
FDA approval · 2025-03-28FDA Approved: LOCAMETZ — Supplemental Application (Advanced Accelerator Applications USA, Inc)
FDA approved a supplemental application for LOCAMETZ to include a kit for the preparation of Gallium-68 gozetotide for PET imaging.
-
EMA approval · 2025-03-10EMA Authorised: Sutent (sunitinib) — Pfizer Limited
Sutent (sunitinib) has been authorised by the EMA with indications for gastrointestinal stromal tumor, renal cell carcinoma, and neuroendocr…
-
FDA approval · 2024-07-01FDA Approved: KIT FOR THE PREPARATION OF INDIUM IN 111 PENTETREOTIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a kit for the preparation of Indium-111 pentetreotide used in imaging neuroendocrine tumors.
-
FDA approval · 2023-10-26FDA Approved: NETSPOT — Supplemental Application (Advanced Accelerator Applications USA, Inc)
FDA approved a supplemental application for NETSPOT (68GA-DOTATATE) from Advanced Accelerator Applications USA, Inc, expanding the labeling …
-
FDA approval · 2023-07-27FDA Approved: GA-68-DOTATOC — Supplemental Application (UIHC P E T Imaging Center)
The FDA approved a supplemental application for GA-68-DOTATOC (edotreotide gallium-68) from the UIHC PET Imaging Center to use this radiopha…
-
FDA approval · 2023-03-15FDA Approved: ILLUCCIX — Supplemental Application (Telix Pharmaceuticals (US) Inc.)
FDA approved a supplemental application for ILLUCCIX, a kit for preparing Gallium-68 gozetotide injection used in PET imaging of neuroendocr…
-
FDA approval · 2023-03-07FDA Approved: LUTATHERA — Supplemental Application (Advanced Accelerator Applications USA, Inc)
FDA approved a supplemental application for LUTATHERA (lutetium Lu-177 dotatate) submitted by Advanced Accelerator Applications USA, Inc. Th…
-
FDA approval · 2022-06-13FDA Approved: LUTATHERA — Supplemental Application (Advanced Accelerator Applications USA, Inc)
FDA approved a supplemental application for LUTATHERA (Lutetium-177 dotatate) from Advanced Accelerator Applications USA, Inc. The action re…
-
FDA approval · 2022-06-06FDA Approved: LUTATHERA — Supplemental Application (Advanced Accelerator Applications USA, Inc)
FDA approves a supplemental application for LUTATHERA (Lutetium Lu-177 dotatate) filed by Advanced Accelerator Applications USA, Inc.
-
FDA approval · 2021-12-22FDA Approved: GA-68-DOTATOC — Supplemental Application (UIHC P E T Imaging Center)
FDA approved a supplemental application for GA-68-DOTATOC (edotreotide gallium-68) for PET imaging, enabling its use in neuroendocrine tumor…
-
FDA approval · 2021-12-22FDA Approved: DETECTNET — Supplemental Application (CURIUM US LLC)
FDA approved a supplemental application for DETECTNET, a copper-64 DOTATATE PET imaging agent from Curium US LLC.
-
FDA approval · 2021-12-22FDA Approved: OCTREOSCAN — Supplemental Application (Curium US LLC)
The FDA approved a supplemental application for OCTREOSCAN (Indium-111 pentetreotide) submitted by Curium US LLC.
-
FDA approval · 2020-09-03FDA Approved: DETECTNET — Original Application (CURIUM US LLC)
FDA approved DETECTNET (Copper-64 DOTATATE) from Curium US LLC for PET imaging of neuroendocrine tumors.
-
FDA approval · 2020-05-29FDA Approved: LUTATHERA — Supplemental Application (Advanced Accelerator Applications USA, Inc)
The FDA approved a supplemental application for LUTATHERA (lutetium Lu-177 dotatate) from Advanced Accelerator Applications USA, Inc., grant…
-
FDA approval · 2020-02-03FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for octreotide acetate from Heritage Pharmaceuticals Inc. (Avet Pharmaceuticals Inc.).
-
FDA approval · 2019-04-11FDA Approved: SANDOSTATIN — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Sandostatin (octreotide acetate) from Novartis Pharmaceuticals Corporation under NDA 019667.
-
FDA approval · 2018-09-27FDA Approved: NETSPOT — Supplemental Application (Advanced Accelerator Applications USA, Inc)
The FDA approved a supplemental application for NETSPOT (68GA-DOTATATE) submitted by Advanced Accelerator Applications USA, Inc.
-
FDA approval · 2018-08-27FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Octreotide acetate from Hikma Pharmaceuticals USA.